Tillkännagivande • Jan 22
Arix Bioscience plc Announces Resignation of Directors Arix Bioscience plc announced that Maureen O'Connell and Isaac Kohlberg have resigned from the Arix Board with effect upon the completion of the Share Purchase. Recent Insider Transactions • Nov 06
Independent Non-Executive Chairman recently bought UK£69k worth of stock On the 2nd of November, Peregrine David Euan Moncreiffe bought around 60k shares on-market at roughly UK£1.15 per share. This transaction amounted to 9.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Peregrine David Euan has been a buyer over the last 12 months, purchasing a net total of UK£409k worth in shares. Reported Earnings • Sep 28
First half 2023 earnings released: EPS: UK£0.10 (vs UK£0.24 loss in 1H 2022) First half 2023 results: EPS: UK£0.10 (up from UK£0.24 loss in 1H 2022). Net income: UK£12.5m (up UK£42.5m from 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance. Tillkännagivande • Sep 28
Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023 Arix Bioscience plc announced resignation of Robert Lyne as Chief Executive Officer. He has decided to step down from his position to pursue a new opportunity and will leave the company by the end of 2023. Tillkännagivande • Sep 15
Arix Bioscience plc to Report First Half, 2023 Results on Sep 27, 2023 Arix Bioscience plc announced that they will report first half, 2023 results on Sep 27, 2023 New Risk • Jul 28
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: UK£89k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Significant insider selling over the past 3 months (UK£89k sold). Recent Insider Transactions • May 04
Independent Non-Executive Chairman recently bought UK£77k worth of stock On the 27th of April, Peregrine David Euan Moncreiffe bought around 75k shares on-market at roughly UK£1.03 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth UK£217k. Peregrine David Euan has been a buyer over the last 12 months, purchasing a net total of UK£475k worth in shares. Reported Earnings • Apr 26
Full year 2022 earnings released Full year 2022 results: Net loss: UK£27.6m (loss narrowed 55% from FY 2021). Recent Insider Transactions • Feb 08
Independent Non-Executive Chairman recently bought UK£217k worth of stock On the 6th of February, Peregrine David Euan Moncreiffe bought around 200k shares on-market at roughly UK£1.09 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Peregrine David Euan has been a buyer over the last 12 months, purchasing a net total of UK£398k worth in shares. Tillkännagivande • Jan 27
Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive Director Arix Bioscience plc announced Dr. Benny Soffer, Non-Executive Director, will step down from the Board on 31 January 2023 in order to spend more time on his other business interests. Price Target Changed • Nov 16
Price target increased to UK£2.56 Up from UK£2.30, the current price target is provided by 1 analyst. New target price is 131% above last closing price of UK£1.11. Stock is down 20% over the past year. The company posted a net loss per share of UK£0.48 last year. Board Change • Nov 16
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). CEO, General Counsel & Director Rob Lyne is the most experienced director on the board, commencing their role in 2021. Senior Independent Director Debra Barker was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Recent Insider Transactions • Nov 04
Independent Non-Executive Chairman recently bought UK£78k worth of stock On the 27th of October, Peregrine David Euan Moncreiffe bought around 75k shares on-market at roughly UK£1.04 per share. This transaction amounted to 41% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth UK£103k. Peregrine David Euan has been a buyer over the last 12 months, purchasing a net total of UK£181k worth in shares. Reported Earnings • Aug 11
First half 2022 earnings released First half 2022 results: Net income: (up UK£38.5m from 1H 2021). Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has increased by 2% per year. Reported Earnings • May 06
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: UK£0.48 loss per share (down from UK£0.97 profit in FY 2020). Net loss: UK£61.1m (down 148% from profit in FY 2020). Revenue exceeded analyst estimates by 19%. Earnings per share (EPS) also surpassed analyst estimates by 995%. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Price Target Changed • Apr 27
Price target increased to UK£2.56 Up from UK£2.30, the current price target is provided by 1 analyst. New target price is 131% above last closing price of UK£1.11. Stock is down 42% over the past year. The company posted earnings per share of UK£0.97 last year. Board Change • Apr 27
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Member of Scientific Advisory Board K. Patel is the most experienced director on the board, commencing their role in 2020. Senior Independent Director Michael Bunbury was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Price Target Changed • Oct 07
Price target increased to UK£2.56 Up from UK£2.30, the current price target is provided by 1 analyst. New target price is 82% above last closing price of UK£1.41. Stock is up 31% over the past year. Executive Departure • Sep 01
Managing Director Christian Schetter has left the company On the 31st of August, Christian Schetter's tenure as Managing Director ended after 1.2 years in the role. We don't have any record of a personal shareholding under Christian's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Reported Earnings • Aug 13
First half 2021 earnings released: UK£0.30 loss per share (vs UK£0.38 profit in 1H 2020) First half 2021 results: Revenue: -UK£32.3m (down 175% from 1H 2020). Net loss: UK£38.5m (down 179% from profit in 1H 2020). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Executive Departure • May 04
Executive Chairman Naseem Amin has left the company On the 30th of April, Naseem Amin's tenure as Executive Chairman ended after 1.4 years in the role. As of December 2020, Naseem personally held 240.80k shares (UK£527k worth at the time). A total of 3 executives have left over the last 12 months. Tillkännagivande • Apr 29
Pfizer Inc. (NYSE:PFE) acquired remaining unknown minority stake in Amplyx Pharmaceuticals, Inc. Pfizer Inc. (NYSE:PFE) acquired remaining unknown minority stake in Amplyx Pharmaceuticals, Inc. on April 28, 2021. DLA Piper LLP (US) served as Pfizer Inc.’s legal advisor for the transaction, while Cooley LLP served as Amplyx’s legal advisor and Evercore as its financial advisor.
Pfizer Inc. (NYSE:PFE) completed the acquisition of an remaining unknown minority stake in Amplyx Pharmaceuticals, Inc. on April 28, 2021. Analyst Estimate Surprise Post Earnings • Mar 10
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 19%. Earnings per share (EPS) also surpassed analyst estimates. Over the next year, revenue is expected to shrink by 100% compared to a 88% growth forecast for the Capital Markets industry in the United Kingdom. Reported Earnings • Mar 10
Full year 2020 earnings released: EPS UK£0.97 (vs UK£0.54 loss in FY 2019) The company reported a soft full year result with weaker revenues and profit margins, although earnings were improved. Full year 2020 results: Revenue: UK£135.8m (down 334% from FY 2019). Net income: UK£126.3m (up UK£196.0m from FY 2019). Profit margin: 93% (down from 120% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Tillkännagivande • Mar 04
Arix Bioscience plc to Report Fiscal Year 2020 Results on Mar 09, 2021 Arix Bioscience plc announced that they will report fiscal year 2020 results on Mar 09, 2021 Valuation Update With 7 Day Price Move • Feb 08
Investor sentiment improved over the past week After last week's 16% share price gain to UK£1.93, the stock is trading at a trailing P/E ratio of 13.8x, up from the previous P/E ratio of 11.9x. This compares to an average P/E of 19x in the Capital Markets industry in the United Kingdom. Total returns to shareholders over the past three years were flat. Is New 90 Day High Low • Dec 29
New 90-day high: UK£2.22 The company is up 99% from its price of UK£1.12 on 30 September 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.30 per share. Recent Insider Transactions • Dec 22
Executive Chairman recently bought UK£377k worth of stock On the 18th of December, Naseem Amin bought around 183k shares on-market at roughly UK£2.06 per share. This was the largest purchase by an insider in the last 3 months. This was Naseem's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Dec 15
Investor sentiment improved over the past week After last week's 17% share price gain to UK£2.10, the stock is trading at a trailing P/E ratio of 15.1x, up from the previous P/E ratio of 12.9x. This compares to an average P/E of 19x in the Capital Markets industry in the United Kingdom. Total returns to shareholders over the past three years are 11%. Is New 90 Day High Low • Dec 11
New 90-day high: UK£1.96 The company is up 104% from its price of UK£0.96 on 11 September 2020. The British market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.30 per share. Valuation Update With 7 Day Price Move • Dec 03
Market bids up stock over the past week After last week's 18% share price gain to UK£1.76, the stock is trading at a trailing P/E ratio of 12.6x, up from the previous P/E ratio of 10.7x. This compares to an average P/E of 19x in the Capital Markets industry in the United Kingdom. Total return to shareholders over the past three years is a loss of 7.9%. Major Estimate Revision • Nov 08
Analysts update estimates The company's losses in 2020 are expected to worsen with analysts lowering their consensus EPS forecasts from -UK£0.004 to -UK£0.099. No change was made to the revenue estimate which at the last update was UK£500.0k. The Capital Markets industry in the United Kingdom is expected to see an average net income growth of 2.6% next year. The consensus price target increased from UK£1.38 to UK£2.34. Share price is up 49% to UK£1.58 over the past week. Tillkännagivande • Nov 06
Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire VelosBio Inc. from A. M. Pappas Life Science Ventures V, LP, a fund of Pappas Capital, LLC, Arix Bioscience plc (LSE:ARIX) and other shareholders for $2.8 billion. Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire VelosBio Inc. from A. M. Pappas Life Science Ventures V, LP, a fund of Pappas Capital, LLC, Arix Bioscience plc (LSE:ARIX) and other shareholders for $2.8 billion on November 5, 2020. The consideration will be paid in cash and is subject to certain customary adjustments. The sale of VelosBio is expected to deliver net proceeds of approximately $185 million to Arix Bioscience plc representing a 12x return on Arix's invested capital. The closing of the transaction, which is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, is expected by the end of 2020. Gibson Dunn & Crutcher LLP acted as the legal advisor and J.P. Morgan Securities LLC acted as financial advisor to Merck & Co., Inc. Cooley LLP acted as the legal advisor and Centerview Partners LLC acted as the financial advisor to VelosBio Inc. Valuation Update With 7 Day Price Move • Nov 06
Market bids up stock over the past week After last week's 50% share price gain to UK£1.60, the stock is trading at a trailing P/E ratio of 11.5x, up from the previous P/E ratio of 7.6x. This compares to an average P/E of 18x in the Capital Markets industry in the United Kingdom. Total return to shareholders over the past three years is a loss of 12%. Is New 90 Day High Low • Nov 06
New 90-day high: UK£1.60 The company is up 109% from its price of UK£0.77 on 07 August 2020. The British market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.19 per share. Price Target Changed • Nov 06
Price target raised to UK£1.71 Up from UK£1.40, the current price target is an average from 3 analysts. The new target price is 6.9% above the current share price of UK£1.60. As of last close, the stock is up 32% over the past year. Is New 90 Day High Low • Oct 01
New 90-day high: UK£1.12 The company is up 29% from its price of UK£0.86 on 03 July 2020. The British market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.20 per share. Tillkännagivande • Aug 10
Arix Bioscience plc to Report First Half, 2020 Results on Sep 08, 2020 Arix Bioscience plc announced that they will report first half, 2020 results on Sep 08, 2020 
